PolyPid (PYPD) Competitors $3.37 -0.08 (-2.32%) Closing price 09/25/2025 04:00 PM EasternExtended Trading$3.40 +0.02 (+0.74%) As of 09/25/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PYPD vs. INFU, AVR, STSS, ELMD, CV, BSGM, STIM, SGHT, CVRX, and KRMDShould you be buying PolyPid stock or one of its competitors? The main competitors of PolyPid include InfuSystem (INFU), Anteris Technologies Global (AVR), Sharps Technology (STSS), Electromed (ELMD), CapsoVision (CV), Biosig Technologies (BSGM), Neuronetics (STIM), Sight Sciences (SGHT), CVRx (CVRX), and KORU Medical Systems (KRMD). These companies are all part of the "medical equipment" industry. PolyPid vs. Its Competitors InfuSystem Anteris Technologies Global Sharps Technology Electromed CapsoVision Biosig Technologies Neuronetics Sight Sciences CVRx KORU Medical Systems PolyPid (NASDAQ:PYPD) and InfuSystem (NYSE:INFU) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability. Do insiders and institutionals hold more shares of PYPD or INFU? 26.5% of PolyPid shares are held by institutional investors. Comparatively, 71.1% of InfuSystem shares are held by institutional investors. 24.7% of PolyPid shares are held by insiders. Comparatively, 11.4% of InfuSystem shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has better earnings and valuation, PYPD or INFU? InfuSystem has higher revenue and earnings than PolyPid. PolyPid is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPolyPidN/AN/A-$29.02M-$3.83-0.88InfuSystem$139.89M1.47$870K$0.2343.83 Which has more risk and volatility, PYPD or INFU? PolyPid has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500. Comparatively, InfuSystem has a beta of 1.82, suggesting that its share price is 82% more volatile than the S&P 500. Do analysts prefer PYPD or INFU? PolyPid presently has a consensus price target of $12.40, suggesting a potential upside of 267.95%. InfuSystem has a consensus price target of $13.50, suggesting a potential upside of 33.93%. Given PolyPid's higher probable upside, analysts clearly believe PolyPid is more favorable than InfuSystem.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PolyPid 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17InfuSystem 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 3 Strong Buy rating(s) 3.75 Is PYPD or INFU more profitable? InfuSystem has a net margin of 1.12% compared to PolyPid's net margin of 0.00%. InfuSystem's return on equity of 2.78% beat PolyPid's return on equity.Company Net Margins Return on Equity Return on Assets PolyPidN/A -453.95% -138.92% InfuSystem 1.12%2.78%1.41% Does the media prefer PYPD or INFU? In the previous week, InfuSystem had 3 more articles in the media than PolyPid. MarketBeat recorded 7 mentions for InfuSystem and 4 mentions for PolyPid. PolyPid's average media sentiment score of 1.10 beat InfuSystem's score of 0.40 indicating that PolyPid is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PolyPid 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive InfuSystem 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryInfuSystem beats PolyPid on 12 of the 16 factors compared between the two stocks. Get PolyPid News Delivered to You Automatically Sign up to receive the latest news and ratings for PYPD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PYPD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PYPD vs. The Competition Export to ExcelMetricPolyPidMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$54.85M$2.55B$5.74B$10.39BDividend YieldN/A54.21%5.75%4.64%P/E Ratio-0.8823.2675.7726.11Price / SalesN/A716.05544.60124.93Price / CashN/A176.2437.5461.24Price / Book4.495.1412.876.30Net Income-$29.02M$32.95M$3.29B$271.03M7 Day Performance-2.32%1.15%0.26%-0.14%1 Month Performance-1.46%4.94%2.85%5.82%1 Year Performance-6.43%0.55%65.65%27.63% PolyPid Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PYPDPolyPid3.2707 of 5 stars$3.37-2.3%$12.40+268.0%-6.9%$54.85MN/A-0.8880Positive NewsHigh Trading VolumeINFUInfuSystem4.1546 of 5 stars$10.28+1.2%$12.50+21.6%+70.0%$210.59M$139.89M171.86410AVRAnteris Technologies Global1.5695 of 5 stars$5.80-0.3%$16.50+184.5%N/A$209.15M$2.70M0.00138STSSSharps Technology0.4721 of 5 stars$8.08-9.1%N/AN/A$208.65MN/A-0.013Gap DownELMDElectromed3.8818 of 5 stars$24.68-0.1%$36.25+46.9%+18.3%$206.00M$64M32.90160Positive NewsCVCapsoVisionN/A$4.34+0.2%$5.50+26.7%N/A$203.00M$12.52M0.0090News CoveragePositive NewsBSGMBiosig Technologies1.6058 of 5 stars$6.35+42.6%$10.00+57.6%+1,773.9%$199.35M$13K0.0050Gap DownHigh Trading VolumeSTIMNeuronetics1.6496 of 5 stars$2.84-1.2%$7.00+146.9%+238.8%$188.13M$111.11M-2.52180SGHTSight Sciences3.5184 of 5 stars$3.51-0.3%$4.42+25.8%-46.7%$183.82M$79.87M-3.66210CVRXCVRx2.7376 of 5 stars$6.96+0.5%$14.00+101.3%-18.0%$183.73M$51.29M-3.35160KRMDKORU Medical Systems2.3572 of 5 stars$3.93-0.3%$4.63+17.7%+45.2%$181.70M$36.85M-43.6780 Related Companies and Tools Related Companies InfuSystem Alternatives Anteris Technologies Global Alternatives Sharps Technology Alternatives Electromed Alternatives CapsoVision Alternatives Biosig Technologies Alternatives Neuronetics Alternatives Sight Sciences Alternatives CVRx Alternatives KORU Medical Systems Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PYPD) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | SponsoredNew Buy Alert: Should you put $1,000 into Oracle (ORCL) now?Barron's is calling this Oracle's "Nvidia Moment..." While the Wall Street Journal is simply calling Oracle...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PolyPid Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PolyPid With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
